SynthesisDiabetologia2011
Associations between single-nucleotide polymorphisms (+45T>G, +276G>T, -11377C>G, -11391G>A) of adiponectin gene and type 2 diabetes mellitus: a systematic review and meta-analysis.
Synthesis in Diabetologia, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 9 syntheses or guidelines pooled it, 96 citations in OpenAlex.
- Meta-analysis of the association between adiponectin SNP 45, SNP 276, and type 2 diabetes mellitus.PloS one · 2020Pooled it
- The polymorphism of rs266729 in adiponectin gene and type 2 diabetes mellitus: A Meta-Analysis.Medicine · 2017Pooled it
- Adiponectin Gene Polymorphisms are Associated with Increased Risk of Colorectal Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2015Pooled it
- Association between ADIPOQ +45T>G polymorphism and type 2 diabetes: a systematic review and meta-analysis.International journal of molecular sciences · 2014Pooled it
- Associations between variants on ADIPOQ and ADIPOR1 with colorectal cancer risk: a Chinese case-control study and updated meta-analysis.BMC medical genetics · 2014Pooled it
- Meta-analysis of the association of ADIPOQ G276T polymorphism with insulin resistance and blood glucose.Endocrine · 2014Pooled it
- Pooled it
- Adiponectin-11377CG gene polymorphism and type 2 diabetes mellitus in the Chinese population: a meta-analysis of 6425 subjects.PloS one · 2013Pooled it
- A meta-analysis of the association between TNF-α -308G>A polymorphism and type 2 diabetes mellitus in Han Chinese population.PloS one · 2013Pooled it
- Association of Adiponectin Gene Polymorphism rs266729 in Obese People with Type Two Diabetes Mellitus in North Bulgaria's Population.International journal of molecular sciences · 2026Article
- Exploring the impact of ADIPOQ gene variants on plasma adiponectin levels and oxidative stress in type 2 diabetes mellitus and diabetic nephropathy in South Indian population: a case-control study.Diabetology international · 2025Article
- The Role of Adiponectin andGenes · 2025Review
- Association of Calpain-10 gene polymorphisms with Type 2 diabetes mellitus: a case-control study from a tertiary care hospital in Pakistan.BMC medical genomics · 2025Article
- Association between adiponectin single nucleotide polymorphisms and the risk of diabetic polyneuropathy.Scientific reports · 2025Article
- Association ofGenes · 2024Article
- LEP (G2548A-G19A) and ADIPOQ (T45G-G276T) gene polymorphisms are associated with markers for metabolic syndrome.Diabetology & metabolic syndrome · 2023Article
- Adiponectin: A Promising Target for the Treatment of Diabetes and Its Complications.Life (Basel, Switzerland) · 2023Review
- ADIPOQ gene (T45G and G276T) single nucleotide polymorphisms and their association with gestational diabetes mellitus in a Filipino population.BMC endocrine disorders · 2023Article
- Association of Adiponectin 45T/G (rs2241766) and Visfatin 4689G/T (rs2110385) Gene Polymorphisms with Susceptibility to Obesity.International journal of preventive medicine · 2023Article
- A Meta-analysis of ADIPOQ rs2241766 polymorphism association with type 2 diabetes.Journal of diabetes and metabolic disorders · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aims/hypothesisThe associations between adiponectin polymorphisms and type 2 diabetes have been studied widely; however, results are inconsistent.
methodsWe searched electronic literature databases and reference lists of relevant articles. A fixed or random effects model was used on the basis of heterogeneity. Sub-group and meta-regression analyses were conducted to explore the sources of heterogeneity.
resultsThere were no statistically significant associations between +45T>G (rs2241766), +276G>T (rs1501299), -11391G>A (rs17300539) and type 2 diabetes risk. However, for -11377C>G (rs266729), the pooled OR (95% CI) for G vs C allele was 1.07 (1.03-1.11, p = 0.001). Subgroup analysis by study design revealed that -11377C>G (rs266729) dominant model (CG+GG vs CC, p = 0.0008) and G vs C allele (p = 0.0004) might be associated with type 2 diabetes risk in population-based case-control studies. After stratification by ethnicity, we found that -11377C>G (rs266729) dominant model (CG+GG vs CC, p = 0.004) and G vs C allele (p = 0.001) might be associated with type 2 diabetes risk in white individuals. In individuals with a family history of diabetes, the presence of -11391G>A (rs17300539) dominant model (GA+AA vs GG) and A vs G allele might be associated with increased risk of type 2 diabetes. CONCLUSIONS/
interpretationThe presence of +45T>G (rs2241766), +276G>T (rs1501299) and -11391G>A (rs17300539) do not appear to influence the development of type 2 diabetes. However, G vs C allele of -11377C>G (rs266729) might be a risk factor for type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.